Shopping Cart
Remove All
Your shopping cart is currently empty
Mupadolimab (CPI-006) is a humanized FC-γR binding deficient IgG1 anti-CD73 antibody with potential anticancer activity and activation of CD73POS B cells.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $222 | In Stock | In Stock | |
| 5 mg | $463 | In Stock | In Stock | |
| 10 mg | $878 | - | In Stock | |
| 25 mg | $1,280 | - | In Stock | |
| 50 mg | $1,760 | - | In Stock |
| Description | Mupadolimab (CPI-006) is a humanized FC-γR binding deficient IgG1 anti-CD73 antibody with potential anticancer activity and activation of CD73POS B cells. |
| In vitro | Mupadolimab induces increased expression of markers associated with B cell maturation and antigen presentation, transformation into plasma cells, as well as increased secretion of IgM and IgG[1]. |
| In vivo | Mupadolimab (10 mg/kg; intraperitoneal injection; once daily for 15 days) stimulates antigen-specific humoral immunity in NSG-SGM3 mice infected with SARS-CoV-2[1]. |
| Synonyms | CPI-006 |
| Molecular Weight | 146.92 kDa |
| Cas No. | 2451856-97-4 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.